ChemicalBook > CAS DataBase List > BRD3308 (BRD 3308)

BRD3308 (BRD 3308)

Product Name
BRD3308 (BRD 3308)
CAS No.
1550053-02-5
Chemical Name
BRD3308 (BRD 3308)
Synonyms
BRD3308;BRD3308 (BRD 3308);BRD3308 >=98% (HPLC);BRD3308, 10 mM in DMSO;4-Acetamido-N-(2-amino-4-fluorophenyl)benzamide;4-(Acetylamino)-N-(2-amino-4-fluorophenyl)benzamide;Benzamide, 4-(acetylamino)-N-(2-amino-4-fluorophenyl)-;β-cells,glucolipotoxicity,inflammatory,BRD-3308,Human immunodeficiency virus,BRD3308,Histone deacetylases,HDAC3,diabetes,HDAC,HIV-1,Inhibitor,Apoptosis,latency,BRD 3308,cytokines,hyperglycaemia,HIV,inhibit,insulin
CBNumber
CB64844594
Molecular Formula
C15H14FN3O2
Formula Weight
287.29
MOL File
1550053-02-5.mol
More
Less

BRD3308 (BRD 3308) Property

Boiling point:
449.9±45.0 °C(Predicted)
Density 
1.382±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO:57.0(Max Conc. mg/mL);198.41(Max Conc. mM)
form 
A solid
pka
12.13±0.70(Predicted)
color 
Off-white to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

Precautionary statements

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML1639
Product name
BRD3308
Purity
≥98% (HPLC)
Packaging
5mg
Price
$154
Updated
2025/07/31
Sigma-Aldrich
Product number
SML1639
Product name
BRD3308
Purity
≥98% (HPLC)
Packaging
25mg
Price
$308
Updated
2025/07/31
Biosynth Carbosynth
Product number
BB168411
Product name
BRD 3308
Packaging
50mg
Price
$332.5
Updated
2021/12/16
ChemScene
Product number
CS-0015975
Product name
BRD3308
Purity
95.94%
Packaging
10mg
Price
$160
Updated
2021/12/16
AK Scientific
Product number
4572DW
Product name
CID72734382
Packaging
10mg
Price
$178
Updated
2021/12/16
More
Less

BRD3308 (BRD 3308) Chemical Properties,Usage,Production

Uses

BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency[1][2][3].

Biological Activity

BRD3308 is a highly selective inhibitor of histone deacetylase 3 (HDAC3) with an IC50 value of 65 nM for HDAC3 vs. IC50 values of 1.08 μM and 1.15 μM for HDAC1 and HDAC2, respectively. BRD3308 protected pancreatic β cells, suppressing inflammatory cytokine-induced apoptosis and increasing insulin release without the toxicity associated with HDAC1 and HDAC2 inhibitors. In a r at model of type 2 diabetes, BRD3308 reduced hyperglycemia and increased insulin secretion without affecting weight gain. In another study, BRD3308 was found to activate HIV-1 transcription, disrupting HIV-1 latency.', 'BRD3308 promotes outgrowth of HIV-1 (human immunodeficiency virus 1) from inactive infected patient cells. It helps to increase β-cell proliferation.

in vivo

BRD3308 (5 mg/kg; intraperitoneal injection; every second day; male Zucker Diabetic Fatty rats) treatment reduces hyperglycaemia and increases insulin secretion in a rat model of type 2 diabetes. At the end of the hyperglycaemic clamp, circulating insulin levels are significantly higher in BRD3308-treated rats. Pancreatic insulin staining and contents are also significantly higher. BRD3308 preserves the functional β-cell mass against glucolipotoxicity in vivo[2].

Animal Model:Male Zucker Diabetic Fatty (Obese) rats (6-week-old)[2]
Dosage:5 mg/kg
Administration:Intraperitoneal injection; every second day
Result:Reduced hyperglycaemia and increased insulin secretion in a rat model of type 2 diabetes.

IC 50

HDAC3: 54 nM (IC50); HDAC3: 29 nM (Ki); HDAC1: 1260 nM (IC50); HDAC1: 5100 nM (Ki); HDAC2: 1340 nM (IC50); HDAC2: 6300 nM (Ki); HIV-1

References

[1] Barton KM, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One. 2014 Aug 19;9(8):e102684. DOI:10.1371/journal.pone.0102684
[2] Lundh M, et al. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab. 2015 Jul;17(7):703-7. DOI:10.1111/dom.12470
[3] Wagner FF, et al. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chem Biol. 2016 Feb 19;11(2):363-74. DOI:10.1021/acschembio.5b00640

BRD3308 (BRD 3308) Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

BRD3308 (BRD 3308) Suppliers

China 41 United States 6 Global 47
BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Country
United States
ProdList
12952
Advantage
65
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Aladdin Scientific
Tel
Email
tp@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
TargetMol Chemicals Inc.
Tel
+1-781-999-5354;
Email
support@targetmol.com
Country
United States
ProdList
39035
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81

1550053-02-5, BRD3308 (BRD 3308)Related Search:


  • BRD3308 (BRD 3308)
  • 4-(Acetylamino)-N-(2-amino-4-fluorophenyl)benzamide
  • BRD3308
  • Benzamide, 4-(acetylamino)-N-(2-amino-4-fluorophenyl)-
  • BRD3308 >=98% (HPLC)
  • 4-Acetamido-N-(2-amino-4-fluorophenyl)benzamide
  • β-cells,glucolipotoxicity,inflammatory,BRD-3308,Human immunodeficiency virus,BRD3308,Histone deacetylases,HDAC3,diabetes,HDAC,HIV-1,Inhibitor,Apoptosis,latency,BRD 3308,cytokines,hyperglycaemia,HIV,inhibit,insulin
  • BRD3308, 10 mM in DMSO
  • 1550053-02-5
  • API